Navigation Links
Anavex advances drug candidate for treatment of Alzheimer's disease
Date:11/28/2007

ease. The brains of mice were injected with amyloid beta peptide, the key ingredient in Alzheimer's brain plaques, which is known to induce histological and biochemical changes, oxidative stress and learning deficits within seven days.

When ANAVEX 1-41 was administered to mice during pre-clinical testing, the compound dose prevented amyloid-beta-induced learning in the spontaneous alternation and passive avoidance performances. In addition, it blocked the induction of amyloid-beta-induced lipid peroxidation, the biochemical process that mediates damage to nerve cell membranes. ANAVEX 1-41 also reduced the loss of pyramidal cells in the hippocampus and blocked the amyloid-beta-induced expression of caspase-3.

ANAVEX 1-41 has been previously shown to reverse learning deficits in mice that were induced by the drugs scopolamine and dizocilpine, or through the administration of amyloid beta peptide. In addition to these findings, the ANAVEX scientific team recently reported the neuroprotective potential of sigma-1 receptor drugs due to their sigma-1 receptor modulatory role on calcium mobilization and signal transduction pathways.

"We are excited by the data that was presented at the Neuroscience 2007 conference regarding the neuroprotective and anti-amnesic properties of ANAVEX 1-41 for Alzheimer's disease," said Dr. Kontzalis, Chief Executive Officer for ANAVEX. "We are committed to further exploring the disease-modifying properties of ANAVEX 1-41 and to meeting our ultimate goal of developing novel therapies to prevent the onset of or slow the progression of Alzheimer's disease."

ANAVEX 1-41 pre-clinical studies will be completed in the coming weeks. Once pre-clinical testing is complete, ANAVEX will commence with IND filing so that human trials of ANAVEX 1-41 can begin.

About Alzheimer's disease

Alzheimer's disease is the most common cause of dementia and is characterized by the progressive degeneration of cognition as a resu
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
2. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
3. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
8. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
9. BioSpace Draws Over 600 Candidates to San Diego Life Science Career Fair
10. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Tobira Therapeutics, Inc. ... the development and commercialization of novel treatments for ... of its merger with Regado Biosciences, Inc. (NASDAQ: ... closing of the merger, Tobira raised $40 million ... investors and all current Tobira institutional investors, including ...
(Date:5/4/2015)... , May 4, 2015   St. Jude ... significantly better computer tool for finding genetic alterations ... but were difficult to identify with whole-genome sequencing. ... Nature Methods . The tool ... Number Segmentation by Regression Tree in Next Generation ...
(Date:5/4/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced today ... 20-F for the fiscal year ended December 31, 2014 ... annual report on Form 20-F contains information regarding its ... area of cancer immune checkpoints. This project aims to ... and binding in targeting certain identified immune checkpoints. The ...
(Date:5/4/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... Roger J Garceau, to its Board of Directors. ... including corporate development and clinical strategy, his appointment ... expertise as Fluorinov transitions to clinical development.  ... pharmaceutical development experience to Fluorinov and most recently ...
Breaking Biology Technology:Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... (Nasdaq: GHDX ) today reported financial results and business ... revenue increased to $49.8 million in the first quarter of 2011, ... revenue was $49.5 million in the first quarter of 2011, an ... quarter of 2010. Net loss was $0.3 million ...
... China, May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ... Company"), a leading China-based biotechnology company focused on ... announced that it will release its first quarter ... market  closes on Wednesday, May 11, 2011 at ...
... 2011 Novavax, Inc. (Nasdaq: NVAX ) will ... Monday, May 9, 2011, before the U.S. financial markets open. ... call hosted by Stanley C. Erck, President and Chief Executive ... Eastern time. The webcast and conference call ...
Cached Biology Technology:Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 2Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 3Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 4Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 5Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 6Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 7Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 83SBio Inc. Schedules Unaudited First Quarter 2011 Results 2
(Date:4/27/2015)... Conn. , Apr. 27, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... commence shipping to pre-order customers the first week of ... through the month of May. ... a significant milestone for the company as Wocket® enters ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Laboratory physicist and his colleagues have found a new ... physics to help solve problems in biology. Specifically, ... shed light on something known as epigenetic memory -- ... some variable condition, such as quality of nutrition or ...
... the Andes mountains of Ecuador have described a new plant ... itself a mini biodiversity hotspot. The new species, Piper ... insect species, most of which are entirely dependent on this ... larger project which focuses on the influence of plant-produced chemical ...
... largely impermeable to proteins, but evolution has provided a way ... study shows in unmatched detail what happens as proteins pass ... a surface membrane and contains internal compartments bounded by membranes. ... through these membranes or be incorporated into them in order ...
Cached Biology News:New application of physics tools used in biology 2New plant species a microcosm of biodiversity 2Protein structure: Peering into the transit pore 2
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... PC, is used to perform runs ... from the Experion automated electrophoresis system. ... and simulated gel views and summarizes ... a Results table. This software is ...
...
Biology Products: